2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation
- PMID: 10807002
- DOI: 10.1016/s0167-4781(99)00138-4
2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation
Abstract
The 2'-position of the carbohydrate moiety has proven to be a fertile position for oligonucleotide modifications for antisense technology. The 2'-modifications exhibit high binding affinity to target RNA, enhanced chemical stability and nuclease resistance and increased lipophilicity. All high binding affinity 2'-modifications have C3'-endo sugar pucker. In addition to gauche effects, charge effects are also important in determining the level of their nuclease resistance. Pharmacokinetic properties of oligonucleotides are altered by 2'-conjugates. For certain modifications (e.g., 2'-F), the configuration at the 2'-position, arabino vs. ribo, determines their ability to activate the enzyme RNase H.
Similar articles
-
An overview of sugar-modified oligonucleotides for antisense therapeutics.Chem Biodivers. 2011 Sep;8(9):1616-41. doi: 10.1002/cbdv.201100081. Chem Biodivers. 2011. PMID: 21922654 Review.
-
2'-Modified oligonucleotides for antisense therapeutics.Curr Top Med Chem. 2007;7(7):641-9. doi: 10.2174/156802607780487713. Curr Top Med Chem. 2007. PMID: 17430205 Review.
-
Nucleosides and nucleotides. 121. Synthesis of oligonucleotides carrying linker groups at the 1'-position of sugar residues.Bioconjug Chem. 1993 Nov-Dec;4(6):499-508. doi: 10.1021/bc00024a012. Bioconjug Chem. 1993. PMID: 8305519
-
Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action.Antisense Nucleic Acid Drug Dev. 2002 Apr;12(2):103-28. doi: 10.1089/108729002760070849. Antisense Nucleic Acid Drug Dev. 2002. PMID: 12074364 Review.
-
Conformationally restricted carbohydrate-modified nucleic acids and antisense technology.Biochim Biophys Acta. 1999 Dec 10;1489(1):167-79. doi: 10.1016/s0167-4781(99)00152-9. Biochim Biophys Acta. 1999. PMID: 10807006 Review.
Cited by
-
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.Mol Ther Nucleic Acids. 2016 May 3;5(5):e317. doi: 10.1038/mtna.2016.26. Mol Ther Nucleic Acids. 2016. PMID: 27138177 Free PMC article.
-
Therapeutic Opportunities for Targeting microRNAs in Cancer.Mol Cell Ther. 2014;2(30):1-13. doi: 10.1186/2052-8426-2-30. Mol Cell Ther. 2014. PMID: 25717380 Free PMC article.
-
Oligonucleotide transition state analogues of saporin L3.Eur J Med Chem. 2017 Feb 15;127:793-809. doi: 10.1016/j.ejmech.2016.10.059. Epub 2016 Oct 27. Eur J Med Chem. 2017. PMID: 27823883 Free PMC article.
-
Role of miRNA-1 and miRNA-21 in Acute Myocardial Ischemia-Reperfusion Injury and Their Potential as Therapeutic Strategy.Int J Mol Sci. 2022 Jan 28;23(3):1512. doi: 10.3390/ijms23031512. Int J Mol Sci. 2022. PMID: 35163436 Free PMC article. Review.
-
Development and application of ribonucleic acid therapy strategies against COVID-19.Int J Biol Sci. 2022 Aug 1;18(13):5070-5085. doi: 10.7150/ijbs.72706. eCollection 2022. Int J Biol Sci. 2022. PMID: 35982905 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous